SUMM.L Regulatory News (SUMM)

30 Apr 2007 07:05

VASTox plc30 April 2007 VASTox plc ("VASTox" or "the Company") VASTOX TO PRESENT DATA FROM DUCHENNE MUSCULAR DYSTROPHY DRUG DISCOVERY PROGRAMME AT LEADING INTERNATIONAL CONFERENCE Oxford, UK, 30 April 2007 - VASTox plc (AIM: VOX), a leading UK biotechnologycompany, announces that Professor Kay Davies, co-founder of VASTox and Chair ofthe Company's Scientific Advisory Board, will be presenting at "The 20thAnniversary of the DMD Gene Discovery: Impact on Muscle, Disease and Therapy"conference, which will take place on 3-5 May 2007 in Ottawa, Canada. This conference, which is being co-sponsored by VASTox, will bring together theworld's pre-eminent scientists in the field of musculoskeletal disease researchfrom commercial and academic backgrounds. Prof. Davies, a leading expert inDuchenne Muscular Dystrophy ("DMD"), will present data from VASTox's unique,disease modifying approach for a DMD therapy at the conference. Also inattendance from VASTox will be the Company's Chief Scientific Officer, RichardStorer, PhD and Director of Programmes, Jon Tinsley, PhD. - ends - For more information please contact: VASToxSteven Lee, PhD, Chief Executive Officer Tel: +44 (0)1235 443951Richard Storer, PhD, Chief Scientific Officer Citigate Dewe RogersonMark Swallow / David Dible / Valerie Auffray Tel: +44 (0)207 638 9571 About VASTox plc VASTox is a leading UK biotechnology company that discovers and developsproprietary new drugs. The Company's internal drug development programmes areunderpinned by its advanced chemistry and drug screening (chemical genomics)technology platforms, which it also provides on a collaborative orfee-for-service basis to the pharmaceutical industry. VASTox has a broad range of drug discovery programmes in the clinical,pre-clinical and discovery stages of development, which target serious diseaseswith a high unmet medical need. These therapeutic areas include neuro-disorders(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,oncology and regenerative medicines. VASTox's in-house drug development capabilities combine world-class expertise inboth medicinal and carbohydrate chemistry with high-volume, high-contentscreening using its proprietary zebrafish and fruitfly technologies (chemicalgenomics). These whole organism screens have the potential to dramaticallydecrease the time and cost of drug discovery and development by delivering data that are highlypredictive of the efficacy and toxicity of potential drug compounds in humans. The company listed on the AIM market of the London Stock Exchange in October2004 - symbol: VOX Further information about the company is available at www.vastox.com This document contains "forward-looking statements" within the meaning of theU.S. Private Securities Litigation Reform Act of 1995. Forward-lookingstatements can be identified by words such as "anticipates", "intends", "plans","seeks", "believes", "estimates", "expects" and similar references to futureperiods, or by the inclusion of forecasts or projections. Forward-looking statements are based on the Company's current expectations andassumptions regarding our business, the economy and other future conditions.Because forward-looking statements relate to the future, by their nature, theyare subject to inherent uncertainties, risks and changes in circumstances thatare difficult to predict. The Company's actual results may differ materiallyfrom those contemplated by the forward-looking statements. The Company cautionsyou therefore that you should not rely on any of these forward-lookingstatements as statements of historical fact or as guarantees or assurances offuture performance. Important factors that could cause actual results to differmaterially from those in the forward-looking statements and regional, national,global political, economic, business, competitive, market and regulatoryconditions. This information is provided by RNS The company news service from the London Stock Exchange